Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease (Q36956720)

17 August 2017

1 reference

title

Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

17 August 2017

1 reference

based on heuristic

inferred from title

systemic inflammation

1 reference

Mario Cazzola

1

1 reference

17 August 2017

Chiara Ciaprini

series ordinal

2

1 reference

17 August 2017

Clive P Page

series ordinal

3

1 reference

17 August 2017

Maria G Matera

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Therapeutic Targets

17 August 2017

1 reference

17 August 2017

11

1 reference

17 August 2017

10

1 reference

17 August 2017

1273-1286

1 reference

Thomas a. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease.

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Chronic obstructive pulmonary disease. 5: systemic effects of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Systemic inflammation and decline in lung function in a general population: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The response of human bone marrow to chronic cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Enhanced neutrophil response in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The interactions between cigarette smoking and reduced lung function on systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Ongoing airway inflammation in patients with COPD who do not currently smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The immune response to resistive breathing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Is loaded breathing an inflammatory stimulus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Beta-adrenergic agonists and hypertrophy of skeletal muscles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effect of beta-agonists on inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The lymphocytic cholinergic system and its biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Controlling inflammation: the cholinergic anti-inflammatory pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The non-neuronal cholinergic system in humans: expression, function and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

COPD: current therapeutic interventions and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Muscarinic receptor signaling in the pathophysiology of asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Why does the lung hyperinflate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

21 January 2018

Theophylline for COPD.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Reduced histone deacetylase in COPD: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

New aspects of the therapeutic potential of theophylline in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Occupancy of P2 purinoceptors with unique properties modulates the function of human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effect of low-dose theophylline on airway inflammation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-alpha in the sputum of patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

C-reactive protein in patients with COPD, control smokers and non-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Inflammation and atherosclerosis: role of C-reactive protein in risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

New molecular targets for the treatment of neutrophilic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Improved expression, purification, and crystallization of p38alpha MAP kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Novel strategies for inhibition of the p38 MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

First study of infliximab treatment in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Are phosphodiesterase 4 inhibitors just more theophylline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Novel drug development opportunities for heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Anti-adhesive glycoproteins in echinoderm mucus secretions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

COPD, a multicomponent disease: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Potential therapeutic role for statins in respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

21 January 2018

Apoptotic cell removal

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Statin use is associated with reduced mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

PPAR-gamma agonists as therapy for diseases involving airway neutrophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

Systemic effects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.10.1273

10.1517/14728222.11.10.1273

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference